Observational studyClinical interventions in aging2026
Cerebral Microbleeds, Anemia, and Estimated Net Benefit of DOACs versus Warfarin in Older Atrial Fibrillation: A Single-Center MRI-Selected Cohort.
Observational study in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Randomized trials favor direct oral anticoagulants (DOACs) over warfarin for eligible atrial fibrillation (AF), but whether cerebral microbleeds (CMBs) and anemia identify older patients with narrower benefit-harm margins remain uncertain. We estimated 2-year net clinical benefit (NCB) overall and by CMB/anemia strata. Methods: This single-center, MRI-selected prospective observational cohort included patients aged ≥65 years with non-valvular AF receiving a DOAC or warfarin. Follow-up began at susceptibility MRI; CMB presence (0 vs ≥1) was rated by two blinded raters, and anemia used World Health Organization hemoglobin thresholds. DOAC-warfarin associations were estimated using propensity-score overlap weighting and competing-risk models for ischemic stroke/systemic embolism (IS/SE) and intracranial hemorrhage (ICH). Two-year NCB was expressed as net events prevented per 1000 with bootstrap 95% confidence intervals (CIs). Results: Among 797 patients (DOAC n=517; warfarin n=280), 31.0% had ≥1 CMB and 33.8% had anemia. During 2463 person-years, 40 first IS/SE events, 22 first ICH events, and 89 deaths occurred as first components of net adverse clinical events (NACE). After weighting, DOAC use was associated with lower NACE (2-year risk 14.9% vs 21.8%; hazard ratio 0.69, 95% CI 0.52-0.91), ICH (1.4% vs 4.3%; subdistribution hazard ratio 0.39, 95% CI 0.21-0.72), and IS/SE (3.9% vs 6.4%; subdistribution hazard ratio 0.63, 95% CI 0.41-0.96). Estimated NCB favored DOACs overall (67.0/1,000; 95% CI 28.4-102.7) and was attenuated in patients with both CMBs and anemia (38.0/1,000; 95% CI 4.2-71.5). Conclusions: DOAC use was associated with a favorable estimated 2-year NCB vs warfarin in this MRI-selected cohort. Combined CMB/anemia findings are exploratory and hypothesis-generating and should not guide prescribing without multicenter validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.